Sushil Singhi, MD
Cardiovascular Disease · Rock Hill, SCNPI 1457304628
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,452 of the $6,387 with a category attached, or 69.7%. 29 manufacturers reported payments, led by Medtronic at 28.3% of the total. Reporting peaked in 2019 at $2,161 and has fallen 70.1% since, to $645 in 2025.
Across 100 payments — averaging $63.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Inspire Medical Systems, Inc.$988
- Janssen Research & Development, LLC$897
- Abiomed$307
- Boehringer Ingelheim$229
- Edwards Lifesciences$227
- plus $2K from 23 others
Across 18 payments — averaging $2677.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$46K
- Biotronik Inc.$2K
What the payments were for
- Travel & lodging$1,83629%
- Food & beverage$4,45270%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 17 | $1,806 |
| Inspire Medical Systems, Inc. | 15 | $988 |
| Janssen Research & Development, LLC | 10 | $897 |
| Abiomed | 4 | $307 |
| Boehringer Ingelheim | 3 | $229 |
| Edwards Lifesciences | 4 | $227 |
| AstraZeneca | 2 | $212 |
| Boston Scientific | 4 | $184 |
| Novo Nordisk | 2 | $182 |
| E.r. Squibb & Sons, L.L.C. | 9 | $165 |
| Atricure, Inc. | 2 | $150 |
| Amarin Pharma, Inc. | 1 | $125 |
| Biotronik Inc. | 1 | $125 |
| Bayer | 1 | $122 |
| Johnson & Johnson | 2 | $112 |
| Heartflow, Inc. | 1 | $111 |
| Abbott | 2 | $110 |
| Amgen | 4 | $66 |
| Tactile Systems Technology Inc | 2 | $49 |
| Lexicon Pharmaceuticals, Inc. | 3 | $47 |
| Kestra Medical Technology Services, Inc. | 2 | $33 |
| Pfizer | 2 | $29 |
| Cvrx, Inc. | 1 | $21 |
| Novartis | 1 | $17 |
| Merck | 1 | $17 |
| Cleerly, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$1,364
- Inspire$663
- Impella$252
- JARDIANCE$211
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$130
- Inspire Upper Airway Stimulation System$130
- AVVIGO Guidance System$130
- Vascepa$125
- Kerendia$122
- Ozempic$121
- FARXIGA$113
- FFRct$111
- XARELTO$103
How this compares
$6,387 in reported general payments places this provider in the 65th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 254 | $289,704 |
| XareltoRivaroxaban | 41 | $46,671 |
| EntrestoSacubitril/Valsartan | 23 | $40,011 |
| FarxigaDapagliflozin Propanediol | 27 | $32,660 |
| BrilintaTicagrelor | 38 | $25,429 |
| Ranolazine ErRanolazine | 93 | $9,309 |
| Rosuvastatin Calcium | 231 | $3,329 |
| Losartan Potassium | 210 | $2,355 |
| Flecainide Acetate | 49 | $2,344 |
| Metoprolol Succinate | 167 | $2,278 |
| ClopidogrelClopidogrel Bisulfate | 195 | $2,136 |
| Atorvastatin Calcium | 221 | $2,022 |
| Metoprolol Tartrate | 267 | $1,613 |
| Amlodipine Besylate | 250 | $1,467 |
| Carvedilol | 213 | $1,459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $29 | $289,704254 claims |
| AstraZenecaFarxiga, Brilinta | $212 | $58,08965 claims |
| Johnson & JohnsonXarelto | $112 | $46,67141 claims |
| NovartisEntresto | $17 | $40,01123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Rock Hill
- Murad AbdelsalamRock Hill$21K
- Robert BiedermanCharleston$775K
- Darren SidneyNorth Charleston$129K
- Priyanka BhattacharyaCharleston$107K
- Gregory SanGreenville$88K
- David McNeelyGreenville$78K
- Gregory EavesAiken$65K
- James SmithCharleston$64K
- Christopher SalmonGreenville$54K
- Ricky HendersonAnderson$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.